Zacks Investment ResearchT3·7d ago
FTXH First Trust Nasdaq Pharmaceuticals ETF
ETF 42.92 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
FTXH
$42.92
—
Key stats
$42.92
- 52-Week Range
- $29.37 – $43.52
- YTD
- +29.57%
- IV Rank (30D)
- 46.82
- Straddle Price
- $2.75
- Open
- $43.14
- Day Range
- $42.67 – $43.40
- Volume
- 54,200
- Prev Close
- $42.75
About
First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2016-09-20
- Has Options
- Yes
Fund profile
holdings as of Oct 20, 2026issuer datathrough Jun 2026flows, SEC filings
- Expense ratio
- 0.60% prospectus, filed Jul 29, 2025
- Assets
- $1.1B issuer-reported, Oct 20, 2026
- Trailing yield
- 0.68% paid quarterly
- Average daily volume
- $10M 30 sessions
- Holdings
- 51 top 10 are 55.3%
- Listed
- Sep 20, 2016 Nasdaq
- Net asset value
- $42.69 issuer, Oct 20, 2026
- 30-day SEC yield
- 0.81% issuer, Sep 30, 2026
- Tracking difference
- -0.88 pts vs index, after fees, FY 2026
Cost23
Liquidity67
Scale76
Diversification51
Moves with. US large-cap stocks (14% of its variance, beta 0.66); Developed markets ex-US over US (6% of its variance, beta 0.36); Long Treasuries (5% of its variance, beta 0.29); Value over growth (4% of its variance, beta 0.40). These factors explain 36% of its daily moves over the last year.
Stated objective. The First Trust Nasdaq Pharmaceuticals ETF (the Fund ) seeks investment results that correspond generally to the price and yield (before the Funds fees and expenses) of an equity index called the Nasdaq US Smart Pharmaceuticals TM Index (the Index ). (from the fund's prospectus)
All 51 holdingsFlow historySimilar fundsOverlap toolAll Health Care ETFs
Fund flows
through Jun 2026SEC filings- Jun 2026
- −$1.8M latest reported month
- Latest 3 months
- +$3.3M +9.1% of assets
- Latest 12 months
- +$13M +36.9% of assets
View as a table
| Month | Net flow |
|---|---|
| Jun 2026 | −$1.8M |
| May 2026 | +$1.7M |
| Apr 2026 | +$3.4M |
| Mar 2026 | $0 |
| Feb 2026 | +$5.3M |
| Jan 2026 | +$1.7M |
| Dec 2025 | +$1.7M |
| Nov 2025 | $0 |
| Oct 2025 | +$1.5M |
| Sep 2025 | $0 |
| Aug 2025 | $0 |
| Jul 2025 | $0 |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| PJPInvesco Pharmaceuticals ETF | 56% | 0.57% | $561M | +32.5% | compare |
| IYHiShares U.S. Healthcare ETF | 48% | 0.37% | $4.5B | +23.2% | compare |
| VHTVanguard Health Care ETF | 46% | 0.09% | $20.1B | +22.7% | compare |
| XLVState Street Health Care Select Sector SPDR ETF | 46% | 0.08% | $47.5B | +23.6% | compare |
| FHLCFidelity MSCI Health Care Index ETF | 45% | 0.08% | $3.8B | +23.2% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Oct 20, 2026issuer data- Holdings vs fair value
- +5.5% 31% under, 20% over · 100% covered
- Price / earnings
- 40.2 17% loss-making · 100% covered
- Price / book · sales
- 4.6 · 4.8 revenue growth +7.0%
- Above 200-day average
- 88% 74% above 50-day · by weight
- Short interest
- 4.8% of float, weighted · 4.4 days to cover
- Insider buying
- 9% of weight had net insider buying, 90 days; 65% net selling
- 13F holders
- +3.4% change in shares held by institutions, latest quarter
- Reporting earnings
- 37.1% of weight in 7 days; 87.7% in 14
Holdings reporting in the next 14 days · weighted implied move this week 3.09%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Dec 31, 2025 → Mar 31, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Decrease | PFEPfizer Inc. | 6.19% | 3.85% | −38.3% |
| Increase | LLYEli Lilly & Co. | 4.52% | 6.62% | +91.8% |
| Increase | ZTSZoetis Inc. | 2.48% | 3.41% | +64.4% |
| Decrease | CAHCardinal Health, Inc. | 4.25% | 3.49% | −10.6% |
| Decrease | ARWRArrowhead Pharmaceuticals Inc | 1.26% | 0.56% | −47.3% |
| Increase | INCYIncyte Corporation. | 1.54% | 2.21% | +68.7% |
| Exit | BBIOBridgebio Pharma Inc | 0.62% | — | — |
| Exit | NEWAMSTERDAM PHARMA CO NV | 0.61% | — | — |
| New position | SYRESpyre Therapeutics Inc | — | 0.61% | — |
| Exit | MDGLMadrigal Pharmaceuticals Inc | 0.56% | — | — |
0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 0.5%. Full holdings and history
Under the hood
fiscal year to Mar 31, 2026SEC census- Authorized participants
- 6 active of 24 with agreements; top 3 did 71%
- Created · redeemed
- $16M · $6.4M over the fiscal year
- Redemptions in kind
- 100% creations 100% in kind
- Creation unit
- 50,000 shares
- Securities lending
- authorized, none lent
- Return vs index
- -0.88 pts after fees; -0.08 before; daily s.d. 0.05
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-10-20
Holdings
51
AUM
$1.1B
Provider
First Trust
Inception
2016-09-20
Exchange
XNAS
Data As Of
2026-10-20
Expense Ratio
0.60%
Dividend Yield
0.68%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-24 | 2026-09-30 | $0.0113 | CD |
| 2026-06-25 | 2026-06-30 | $0.0920 | CD |
| 2026-03-26 | 2026-03-31 | $0.0573 | CD |
| 2025-12-12 | 2025-12-31 | $0.1294 | CD |
| 2025-09-25 | 2025-09-30 | $0.1453 | CD |
| 2025-06-26 | 2025-06-30 | $0.0892 | CD |
Asset Allocation
Top Holdings
top 50 of 51 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| ABBV | AbbVie Inc. | 7.83% | Equity (US) | US |
| LLY | Eli Lilly and Company | 7.70% | Equity (US) | US |
| PFE | Pfizer Inc. | 7.35% | Equity (US) | US |
| MRK | Merck & Co., Inc. | 6.97% | Equity (US) | US |
| JNJ | Johnson & Johnson | 6.77% | Equity (US) | US |
| VTRS | Viatris Inc. | 3.92% | Equity (US) | US |
| BIIB | Biogen Inc. | 3.90% | Equity (US) | US |
| GILD | Gilead Sciences, Inc. | 3.71% | Equity (US) | US |
| ZTS | Zoetis Inc. | 3.60% | Equity (US) | US |
| AMGN | Amgen Inc. | 3.54% | Equity (US) | US |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.51% | Equity (US) | US |
| UTHR | United Therapeutics Corporation | 3.34% | Equity (US) | US |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.28% | Equity (US) | US |
| INCY | Incyte Corporation | 3.25% | Equity (US) | US |
| BMY | Bristol-Myers Squibb Company | 3.20% | Equity (US) | US |
| EXEL | Exelixis, Inc. | 2.49% | Equity (US) | US |
| JAZZ | Jazz Pharmaceuticals Plc | 2.36% | Equity (Foreign) | IE |
| ILMN | Illumina, Inc. | 2.15% | Equity (US) | US |
| HALO | Halozyme Therapeutics, Inc. | 1.73% | Equity (US) | US |
| MEDP | Medpace Holdings, Inc. | 1.49% | Equity (US) | US |
| NBIX | Neurocrine Biosciences, Inc. | 1.16% | Equity (US) | US |
| ALNY | Alnylam Pharmaceuticals, Inc. | 1.15% | Equity (US) | US |
| BMRN | BioMarin Pharmaceutical Inc. | 1.15% | Equity (US) | US |
| ELAN | Elanco Animal Health Incorporated | 1.13% | Equity (US) | US |
| CRL | Charles River Laboratories International, Inc. | 1.06% | Equity (US) | US |
| IOVA | Iovance Biotherapeutics, Inc. | 0.88% | Equity (US) | US |
| MRNA | Moderna, Inc. | 0.83% | Equity (US) | US |
| CAI | Caris Life Sciences, Inc. | 0.59% | Equity (US) | US |
| TXG | 10X Genomics, Inc. (Class A) | 0.55% | Equity (US) | US |
| AMRX | Amneal Pharmaceuticals, Inc. | 0.55% | Equity (US) | US |
| TNGX | Tango Therapeutics, Inc. | 0.53% | Equity (US) | US |
| LGND | Ligand Pharmaceuticals Inc. (Class B) | 0.52% | Equity (US) | US |
| CORT | Corcept Therapeutics Inc. | 0.50% | Equity (US) | US |
| TWST | Twist Bioscience Corporation | 0.50% | Equity (US) | US |
| GH | Guardant Health, Inc. | 0.49% | Equity (US) | US |
| ROIV | Roivant Sciences Ltd. | 0.49% | Equity (US) | US |
| SYRE | Spyre Therapeutics, Inc. | 0.49% | Equity (US) | US |
| TGTX | TG Therapeutics, Inc. | 0.48% | Equity (US) | US |
| ADPT | Adaptive Biotechnologies Corporation | 0.47% | Equity (US) | US |
| KYMR | Kymera Therapeutics, Inc. | 0.46% | Equity (US) | US |
| ALKS | Alkermes Plc | 0.45% | Equity (Foreign) | IE |
| PTGX | Protagonist Therapeutics, Inc. | 0.45% | Equity (US) | US |
| KRYS | Krystal Biotech, Inc. | 0.44% | Equity (US) | US |
| ORKA | Oruka Therapeutics, Inc. | 0.41% | Equity (US) | US |
| TVTX | Travere Therapeutics, Inc. | 0.38% | Equity (US) | US |
| DNTH | Dianthus Therapeutics, Inc. | 0.36% | Equity (US) | US |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 0.35% | Equity (US) | US |
| ACAD | ACADIA Pharmaceuticals Inc. | 0.34% | Equity (US) | US |
| ELVN | Enliven Therapeutics Inc. | 0.34% | Equity (US) | US |
| LQDA | Liquidia Technologies, Inc. | 0.26% | Equity (US) | US |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 2.51% | -4.32% | 0.27% | -0.99% | 2.65% | 2.36% | 0.41% |
| Feb | -2.11% | -2.35% | -4.78% | 1.59% | 1.74% | 3.56% | -0.39% |
| Mar | -1.81% | 6.34% | -1.06% | -0.08% | -2.44% | -3.16% | -0.37% |
| Apr | 0.21% | -2.88% | 1.04% | -6.38% | -2.69% | -2.00% | -2.12% |
| May | -0.97% | 1.92% | -5.04% | 0.52% | 0.55% | 3.59% | 0.09% |
| Jun | 1.41% | 1.66% | 1.97% | 1.49% | -0.04% | 11.02% | 2.92% |
| Jul | 0.73% | -1.93% | 1.63% | 4.72% | -1.40% | 2.28% | 1.00% |
| Aug | 0.76% | -4.31% | 2.01% | 2.76% | 6.04% | 7.17% | 2.40% |
| Sep | -2.63% | -4.53% | -5.41% | -1.55% | 1.23% | -0.35% | -2.21% |
| Oct | 1.94% | 8.72% | -5.50% | -1.65% | 1.68% | 5.54%* | 1.79% |
| Nov | -4.21% | 5.48% | 3.27% | 0.08% | 10.52% | -- | 3.03% |
| Dec | 4.76% | -2.93% | 5.95% | -4.97% | 1.15% | -- | 0.79% |
| Total | 0.25% | -0.29% | -6.29% | -4.88% | 19.89% | 33.38% | 7.01% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $41.42
SMA 50: $41.38
SMA 200: $36.90
Current: $42.92
EMA 12: $41.88
EMA 26: $41.50
MACD: 0.3749 | Signal: 0.2019
BULLISH
ADX (14): 20.70
WEAK TREND
+DI: 36.51
−DI: 17.27
Momentum Oscillators
RSI (14): 64.46
NEUTRAL
Stoch %K: 94.69
Stoch %D: 81.03
Williams %R: -13.10
Volume & Volatility
BB Upper: $42.92
BB Lower: $39.93
NEUTRAL
OBV: 38,495,062
Vol SMA 20: 349,476
Vol ROC: 46.60%
ATR: $0.74
True Range: $0.73
HV 20: 18.9%
HV 30: 17.1%
HV 60: 19.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report: FTXH
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a strong trend, with MACD indicating bullish momentum
- Recent news headlines are neutral or positive, contributing to the overall neutral assessment
Primary Risks:
- Overbought conditions on Bollinger Bands and RSI, potentially leading to a pullback or consolidation
- Options market signals indicate high IV premium, which may not be justified by historical volatility levels
Investment Thesis: FTXH appears to be in a strong uptrend, supported by technical indicators. However, the stock is overbought, and there are concerns about the sustainability of this move.
Recent News Sentiment Impact: The recent news headlines have been neutral or positive, which has contributed to the overall bullish sentiment.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Resistance: $42.08 (Bollinger Bands upper)
- Support: $37.84 (Bollinger Bands lower)
Momentum Signals:
- RSI interpretation: Overbought (>70), with a value of 69.52
- MACD signal: Bullish crossover above signal line, indicating momentum remains strong
- Bollinger Bands position: Overbought
Volume Analysis: Volume trends and institutional interest signals suggest low volatility, which may indicate a lack of participation in the current uptrend.
News & Sentiment Analysis
Recent Headlines Summary: Neutral headlines dominated, with no significant negative news impacting sentiment.
Sentiment Assessment: Aggregate news sentiment is neutral, with only one headline indicating positive sentiment.
Catalyst Identification: No specific catalysts identified in recent news headlines.
Market Narrative: The neutral market narrative suggests that FTXH's price movement is driven by technical factors rather than significant news events.
Risk & Volatility Assessment
Beta Interpretation: Beta is low (0.41), indicating a relatively stable stock with less volatility than the broader market.
Volatility Regime: Current volatility levels are low, which may indicate a lack of participation in the current uptrend.
Options Market Signals:
- IV rank: 54.3% (Medium)
- Put/call ratios: 0.00 (Bullish sentiment)
Downside Protection: Support levels at $37.84 and risk management considerations should be considered for traders entering long positions.
Market Context & Positioning
Sector Performance: FTXH's performance is mixed relative to the broader healthcare sector, with a slightly stronger trend in recent weeks.
Institutional Activity: Institutional volume patterns suggest low participation in the current uptrend, which may indicate that institutional investors are not yet convinced of the stock's upward trajectory.
Correlation Analysis: Correlation analysis suggests that FTXH moves relatively independently of the broader market, with an R-squared value of 0.30.
Relative Valuation: FTXH is positioned within a trading range, with no significant overvaluation or undervaluation relative to its peers.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $42.08
- Support: $37.84
Breakout/Breakdown Levels: A breakout above the upper Bollinger Bands resistance level ($42.08) could signal continued upward momentum, while a breakdown below the lower support level ($37.84) may indicate a pullback or consolidation.
Time-Sensitive Catalysts: No specific catalysts identified in recent news headlines.
Risk Management: Stop-loss levels and position sizing considerations should be implemented to manage risk for traders entering long positions.
By analyzing the data, I have provided an overall assessment of FTXH's stock performance. The technical indicators suggest a strong uptrend, while the news headlines are neutral or positive. However, there are concerns about the sustainability of this move due to overbought conditions and high IV premium.
Generated
News
All FTXH news →
Zacks Investment ResearchT3·14d ago
Zacks Investment ResearchT3·17d ago
BenzingaT3·8mo ago
Zacks Investment ResearchT3·29mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·32mo ago
Zacks Investment ResearchT3·35mo ago
Zacks Investment ResearchT3·36mo ago
Zacks Investment ResearchT3·38mo ago
Showing 1–10 of 29
Page 1 of 3
FTXH Options Activity & IV Rank
FTXH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 38.5%
7-DTE IV: —
Expected Move: $2.75
7-DTE Move: $2.75
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 0
Put Volume: 0
P/C Volume: —
Call OI: 0
Put OI: 0
P/C OI: —
Total OI: 0
ATM Options Pricing
ATM Call: $1.40
ATM Put: $1.35
Call %: 3.3%
Put %: 3.1%
Chain Summary
Chain Volume: 0
Chain OI: 0
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 25.4% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)46.8MediumOct 22
Straddle Price (30 DTE)$2.75Oct 22
Beta Analysis
Risk Metrics
Beta: 0.3993
Alpha: 34.38%
Correlation: 0.2860
R-Squared: 8.2%
Stock Volatility: 17.8%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
FTXH Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.47K
SI % of Float
0.04%
Days to Cover
1.00
Short Vol Ratio
77.7%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-21
FTXH Constituent Performance
Click any bar to view the full quote for that stock.
FTXH Constituents (50 of 50)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 7.83% | $284.39 | -0.14% | +0.35% | +7.27% |
| LLY | Eli Lilly and Company | 7.70% | $1313.99 | +3.40% | +4.98% | +11.18% |
| PFE | Pfizer Inc. | 7.35% | $30.23 | +1.26% | +2.67% | +6.39% |
| MRK | Merck & Co., Inc. | 6.97% | $147.79 | -1.39% | +1.79% | -0.13% |
| JNJ | Johnson & Johnson | 6.77% | $268.11 | +4.01% | +5.85% | -0.95% |
| VTRS | Viatris Inc. | 3.92% | $18.48 | +0.14% | +1.40% | +6.06% |
| BIIB | Biogen Inc. | 3.90% | $250.65 | +4.01% | +6.50% | +10.73% |
| GILD | Gilead Sciences, Inc. | 3.71% | $156.25 | +1.75% | -0.71% | +4.38% |
| ZTS | Zoetis Inc. | 3.60% | $81.67 | +2.58% | +4.15% | +16.23% |
| AMGN | Amgen Inc. | 3.54% | $448.97 | +2.43% | +3.44% | +10.57% |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.51% | $819.66 | +1.74% | +2.93% | +2.97% |
| UTHR | United Therapeutics Corporation | 3.34% | $590.41 | +4.78% | +9.03% | +25.03% |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.28% | $535.89 | +2.17% | +5.34% | +2.59% |
| INCY | Incyte Corporation | 3.25% | $115.43 | +1.76% | +1.91% | -7.24% |
| BMY | Bristol-Myers Squibb Company | 3.20% | $63.03 | +3.13% | +4.07% | +2.50% |
| EXEL | Exelixis, Inc. | 2.49% | $65.23 | +1.01% | +3.82% | +12.56% |
| JAZZ | Jazz Pharmaceuticals Plc | 2.36% | $212.94 | +0.46% | -0.69% | -9.88% |
| ILMN | Illumina, Inc. | 2.15% | $262 | -7.37% | -2.21% | -4.34% |
| HALO | Halozyme Therapeutics, Inc. | 1.73% | $123.45 | -1.10% | +1.60% | +7.15% |
| MEDP | Medpace Holdings, Inc. | 1.49% | $668.5 | +0.91% | +6.35% | +7.72% |
| NBIX | Neurocrine Biosciences, Inc. | 1.16% | $142.46 | +0.81% | +4.02% | +2.53% |
| BMRN | BioMarin Pharmaceutical Inc. | 1.15% | $56.25 | +1.88% | +0.36% | -8.31% |
| ALNY | Alnylam Pharmaceuticals, Inc. | 1.15% | $228.25 | +1.40% | -2.47% | -8.55% |
| ELAN | Elanco Animal Health Incorporated | 1.13% | $22.75 | +0.86% | -3.38% | +1.77% |
| CRL | Charles River Laboratories International, Inc. | 1.06% | $343.79 | -0.31% | +12.26% | +16.76% |
| IOVA | Iovance Biotherapeutics, Inc. | 0.88% | $13.88 | -5.10% | -5.74% | +28.47% |
| MRNA | Moderna, Inc. | 0.83% | $187.88 | -23.57% | -20.56% | -3.56% |
| CAI | Caris Life Sciences, Inc. | 0.59% | $31.14 | -3.76% | -1.97% | -3.52% |
| AMRX | Amneal Pharmaceuticals, Inc. | 0.55% | $20.37 | +0.84% | +5.82% | +2.85% |
| TXG | 10X Genomics, Inc. (Class A) | 0.55% | $68.69 | -9.13% | -5.11% | -18.33% |
| TNGX | Tango Therapeutics, Inc. | 0.53% | $27.05 | +0.26% | +19.16% | +9.83% |
| LGND | Ligand Pharmaceuticals Inc. (Class B) | 0.52% | $308.23 | -2.08% | +3.26% | +3.07% |
| CORT | Corcept Therapeutics Inc. | 0.50% | $108.91 | -6.34% | -3.93% | -8.10% |
| TWST | Twist Bioscience Corporation | 0.50% | $134.42 | -9.86% | -6.97% | -26.96% |
| ROIV | Roivant Sciences Ltd. | 0.49% | $37.27 | +1.28% | +9.49% | +3.16% |
| SYRE | Spyre Therapeutics, Inc. | 0.49% | $91.87 | -1.16% | +14.69% | +5.49% |
| GH | Guardant Health, Inc. | 0.49% | $160.88 | -3.47% | -3.01% | -8.82% |
| TGTX | TG Therapeutics, Inc. | 0.48% | $52.97 | -0.44% | -5.42% | -7.92% |
| ADPT | Adaptive Biotechnologies Corporation | 0.47% | $24.39 | -3.71% | -4.65% | -17.52% |
| KYMR | Kymera Therapeutics, Inc. | 0.46% | $111.31 | -1.17% | +2.93% | -3.89% |
| ALKS | Alkermes Plc | 0.45% | $44.45 | +2.23% | +10.85% | +8.97% |
| PTGX | Protagonist Therapeutics, Inc. | 0.45% | $139.53 | +1.05% | +2.18% | +1.59% |
| KRYS | Krystal Biotech, Inc. | 0.44% | $319 | -0.98% | -3.33% | -7.53% |
| ORKA | Oruka Therapeutics, Inc. | 0.41% | $80.61 | +0.87% | +9.13% | -5.70% |
| TVTX | Travere Therapeutics, Inc. | 0.38% | $52.6 | +0.05% | -0.35% | -13.22% |
| DNTH | Dianthus Therapeutics, Inc. | 0.36% | $76.48 | -2.07% | +2.62% | -15.68% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 0.35% | $57.73 | -1.89% | -1.32% | -12.63% |
| ACAD | ACADIA Pharmaceuticals Inc. | 0.34% | $20.27 | +0.42% | +2.87% | -8.59% |
| ELVN | Enliven Therapeutics Inc. | 0.34% | $41.73 | -0.23% | +6.09% | -7.63% |
| LQDA | Liquidia Technologies, Inc. | 0.26% | $39.54 | +1.75% | +13.69% | -44.27% |